Research programme: dementia therapeutics: Autifony Therapeutics

Drug Profile

Research programme: dementia therapeutics: Autifony Therapeutics

Alternative Names: Voltage-gated ion channel therapeutics - Autifony Therapeutics

Latest Information Update: 21 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Autifony Therapeutics
  • Class
  • Mechanism of Action Voltage-gated potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Dementia

Most Recent Events

  • 15 Mar 2017 Early research in Dementia in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top